NO950030L - Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose - Google Patents

Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose

Info

Publication number
NO950030L
NO950030L NO950030A NO950030A NO950030L NO 950030 L NO950030 L NO 950030L NO 950030 A NO950030 A NO 950030A NO 950030 A NO950030 A NO 950030A NO 950030 L NO950030 L NO 950030L
Authority
NO
Norway
Prior art keywords
ring
toxoplasmosis
treatment
infection
spiropiperidyl
Prior art date
Application number
NO950030A
Other languages
English (en)
Other versions
NO950030D0 (no
Inventor
Jack S Remington
Fausto G Araujo
Original Assignee
Palo Alto Medical Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/203,539 external-priority patent/US5529994A/en
Application filed by Palo Alto Medical Found filed Critical Palo Alto Medical Found
Publication of NO950030D0 publication Critical patent/NO950030D0/no
Publication of NO950030L publication Critical patent/NO950030L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåte for å redusere alvorlighetsgraden ved toksoplasmose som skyldes infeksjon hos en pasient med Toxoplasma gondii, ved at det til den behandlingstrengende pasient, enten etter infeksjon eller før eksponering overfor slik infeksjon, administreres en terapeutisk effektiv mengde av en forbindelse som er et spiropiperidyl-derivat av rifamycin S, hvor derivatet omfatter en imidazolring som innbefatter karbonatomer i rifamycinringens 3- og 4- stillinger, idet karbonet i 2-stilling av imidazolringen også utgjør et ringkarbon i 4-stilling i et piperidin-ringsystem, hvorved det dannes et spiropiperidyl-ringsystem, hvor spiro- piperidyl-ringsystemet eventuelt omfatter en lavere hydrokarbon-substituent på piperidinets nitrogen.
NO950030A 1993-05-05 1995-01-04 Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose NO950030L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5728893A 1993-05-05 1993-05-05
US08/203,539 US5529994A (en) 1993-05-05 1994-02-28 Treatment for toxoplasmosis
PCT/US1994/004765 WO1994025038A1 (en) 1993-05-05 1994-04-29 Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis

Publications (2)

Publication Number Publication Date
NO950030D0 NO950030D0 (no) 1995-01-04
NO950030L true NO950030L (no) 1995-01-04

Family

ID=26736295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950030A NO950030L (no) 1993-05-05 1995-01-04 Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose

Country Status (14)

Country Link
US (5) US5670496A (no)
EP (1) EP0648121B1 (no)
JP (1) JPH07509003A (no)
AT (1) ATE143601T1 (no)
AU (1) AU669300B2 (no)
CA (1) CA2138643A1 (no)
DE (1) DE69400631T2 (no)
DK (1) DK0648121T3 (no)
ES (1) ES2095772T3 (no)
GR (1) GR3021828T3 (no)
IL (1) IL109543A (no)
NO (1) NO950030L (no)
RU (1) RU2121838C1 (no)
WO (1) WO1994025038A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
AU3760400A (en) * 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
US7074832B2 (en) 2001-09-24 2006-07-11 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US6429231B1 (en) * 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US6858083B2 (en) * 2002-06-05 2005-02-22 Scimed Lifesystems, Inc. Apparatus and method for closed-loop control of RF generator for welding polymeric catheter components
US20030017985A1 (en) * 2002-07-02 2003-01-23 Taylor Gregory Alan Molecules that influence pathogen resistance
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
TW201233389A (en) 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
US7799885B2 (en) 2005-11-30 2010-09-21 Corning Incorporated Photo or electron beam curable compositions
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
SG170028A1 (en) * 2006-02-24 2011-04-29 Callida Genomics Inc High throughput genome sequencing on dna arrays
RU2320337C1 (ru) * 2006-06-09 2008-03-27 Федеральное государственное унитарное предприятие "Государственный научный центр по антибиотикам" Способ получения антимикробной композиции с рифабутином
FR2944014A1 (fr) 2009-04-06 2010-10-08 Univ Grenoble 1 Peptides cycliques a activite antiparasitaire
CN114601840A (zh) * 2020-12-08 2022-06-10 复旦大学附属中山医院 一种联合用药,用于治疗卡氏肺孢子虫肺炎
CN113230248A (zh) * 2021-06-18 2021-08-10 宁波大学 利卡灵-b及其组合物在制备治疗或预防弓形虫病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644616A (en) * 1969-03-24 1972-02-22 Ciba Geigy Corp Synergistic composition of rifampicin and streptomycin
US4054663A (en) * 1974-12-23 1977-10-18 Sankyo Company Limited Pyridine derivatives and their use as anticoccidial agents
US4094982A (en) * 1975-05-15 1978-06-13 Sankyo Company Limited Pyridine sulfonamides and their use as anticoccidial agents
IT1056272B (it) * 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
IT1135270B (it) * 1980-04-12 1986-08-20 Erba Farmitalia 3-amidino-ansamicine
US5175319A (en) * 1983-04-14 1992-12-29 Burroughs Wellcome Co. Naphthoquinone derivatives
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
DE3512194A1 (de) * 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
GB9000241D0 (en) * 1990-01-05 1990-03-07 Coopers Animal Health Pharmaceutical use
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis

Also Published As

Publication number Publication date
IL109543A (en) 1998-06-15
EP0648121A1 (en) 1995-04-19
US5650405A (en) 1997-07-22
IL109543A0 (en) 1994-08-26
WO1994025038A1 (en) 1994-11-10
EP0648121B1 (en) 1996-10-02
US5648345A (en) 1997-07-15
DE69400631T2 (de) 1997-02-27
ATE143601T1 (de) 1996-10-15
RU2121838C1 (ru) 1998-11-20
NO950030D0 (no) 1995-01-04
AU6905094A (en) 1994-11-21
US5641769A (en) 1997-06-24
AU669300B2 (en) 1996-05-30
US5665707A (en) 1997-09-09
DK0648121T3 (no) 1997-02-24
ES2095772T3 (es) 1997-02-16
RU95105973A (ru) 1997-01-20
CA2138643A1 (en) 1994-11-10
DE69400631D1 (de) 1996-11-07
GR3021828T3 (en) 1997-02-28
US5670496A (en) 1997-09-23
JPH07509003A (ja) 1995-10-05

Similar Documents

Publication Publication Date Title
NO950030D0 (no) Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose
AU653415B2 (en) Method of treating ocular inflammation
LU91037I2 (fr) Somatulina autogel
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
ATE133861T1 (de) Antihypertensive zubereitungen und deren verwendung
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
FR2630328B1 (fr) Derive de l'histamine, sa preparation et son application en therapeutique
HUP9802087A2 (hu) Eljárás mánia és bipoláris rendellenesség kezelésére alkalmas gyógyászati készítmények előállítására
EP0361645A3 (en) Organic hydrazine derivatives for pharmaceutical use
IE46171L (en) N-pyrrolidinylmethylbenzamide derivative.
FI884960A0 (fi) Anvaendning av 2-pyrimidinyl-1-piperazin-derivat.
DE69200365D1 (de) Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria.
KR880004810A (ko) 소화성 궤양 치료제
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
KR920003972A (ko) 프로스타시클린 화합물을 이용한 백내장 치료
FI892685A0 (fi) Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
EP0260790A3 (en) Use of pinacidil in the treatment of incontinence
DK0728002T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 7-infektioner
NZ336249A (en) parenteral composition of a dihydropolyprenol and a pharmaceutically acceptable oil
WO2001005384A3 (en) Manumycin derivatives for treating parasitic disorders
FR2699919B1 (fr) Dérivés d'imidazole, leur procédé de préparation et leur application en thérapeutique.
KR940002268A (ko) 21-클로로-프레그난 유도체
GB9323403D0 (en) Pharmaceuticals
FR2693194B1 (fr) Dérivés d'alcanecarboxamide, leur préparation et leur application thérapeutique.